COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03020017
Recruitment Status : Active, not recruiting
First Posted : January 13, 2017
Last Update Posted : August 22, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Priya Kumthekar, Northwestern University

Tracking Information
First Submitted Date  ICMJE January 11, 2017
First Posted Date  ICMJE January 13, 2017
Last Update Posted Date August 22, 2018
Actual Study Start Date  ICMJE May 4, 2017
Estimated Primary Completion Date July 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 11, 2017)
Incidence of Adverse Events [ Time Frame: Up to 28 days after study drug administration ]
To evaluate the safety of intravenous NU-0129 in patients with recurrent GBM or GS, the number of adverse events will be assessed and will be graded according to the NCI's Common Terminology Criteria in Adverse Events (CTCAE) version 4.03.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 11, 2017)
  • Drug concentration in blood after drug administration [ Time Frame: At 1, 3, 5, 10, 30, and 60 minutes, and 4, 8, and 24 hours post infusion ]
    Blood samples will be collected post-infusion to analyze drug concentration at specific time points after drug administration.
  • Biodistribution of NU-0129 in tumor tissue [ Time Frame: Up to 2 years ]
    Tissue will be collected during the scheduled surgery and assayed with Inductively Coupled Plasma Mass Spectrometry (ICPMS) to analyze the concentration of particles in various parts of tumor tissue.
  • Feasibility of giving NU-0129 as a standard treatment [ Time Frame: Up to 2 years ]
    Feasibility will be calculated as the rate of successful production, delivery, and administration of the investigational product and subsequent resection.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
Official Title  ICMJE A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
Brief Summary The purpose of this research study is to evaluate the safety of the study drug, NU-0129, based on Spherical Nucleic Acid (SNA) platform when infused in patients with recurrent glioblastoma multiforme or gliosarcoma. The SNA consists of nucleic acids arranged on the surface of a small spherical gold nanoparticle. This is a first-in-human trial to determine the safety of NU-0129. NU-0129 can cross the blood brain barrier (a filtering mechanism that carry blood to the brain). Once within the tumor, the nucleic acid component is able to target a gene called Bcl2L12 that is present in glioblastoma multiforme, and is associated with tumor growth. This gene prevents tumor cells from apoptosis, which is the process of programmed cell death, thus promoting tumor growth. Researchers think that targeting the Bcl2L12 gene with NU-0129 will help stop cancer cells from growing.
Detailed Description


I. To assess the safety of intravenous NU-0129 in patients with recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS).


I. To analyze drug concentration in serum at specific time points after drug administration.

II. To demonstrate intratumoral penetration of NU-0129. III. To assess the feasibility of giving NU-0129 as a standard treatment for recurrent GBM or GS.


I. To analyze tumor tissue for Bcl2L12 expression levels after NU-0129 administration.

II. Preliminary response (progression free survival [PFS] and overall survival [OS] at 6 months; overall response rate [ORR]).


Patients receive NU-0129 intravenously (IV) over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.

After completion of study treatment, patients are followed up at 7, 14, 21, and 28 days and then every 84 days for up to 2 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Gliosarcoma
  • Recurrent Glioblastoma
Intervention  ICMJE
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Other: Pharmacological Study
    Correlative studies
  • Drug: Targeted Molecular Therapy
    Given NU-0129 IV
    Other Name: molecularly targeted therapy
Study Arms  ICMJE Experimental: Treatment (NU-0129)
Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Drug: Targeted Molecular Therapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: January 11, 2017)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2022
Estimated Primary Completion Date July 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must have histologically proven glioblastoma multiforme (GBM) or gliosarcoma (GS)
  • Patients must have measurable disease by Response Assessment in Neuro-Oncology (RANO) 2010 criteria at the time of registration (pre-operative)
  • Patients must have failed at least one regimen of chemo or radiation therapy; NOTE: There is no limit to the number or types of prior therapy
  • The patient must be a candidate for surgical debulking (either subtotal or gross total resection); biopsy-only candidates will not be eligible
  • All patients must be capable to voluntarily sign an informed consent indicating that they are aware of the investigational nature of this study prior to registration
  • Patients must have a Karnofsky performance status of >= 70
  • Patients must have adequate bone marrow, liver, coagulation and renal function within 7days prior to study registration, as defined below:
  • White blood cell count (WBC) >= 3,000/uL
  • Absolute neutrophil count (ANC) >= 1,500/mm^3
  • Platelet count of >= 100,000/mm^3 (Note: Transfusion or growth factor may be used for eligibility outside of 7 days)
  • Hemoglobin >= 8 mg/dL (Note: Transfusion may be used for eligibility outside of 7 days)
  • Bilirubin =< 2 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN
  • Creatinine =< 1.5 x ULN
  • Urine protein =< 3 x ULN
  • Cholesterol =< 300 mg/dL
  • International normalized ration (INR) =< 1.5 x ULN
  • Prothrombin time (PT)/partial thromboplastin time (PTT) =< 1.5 x ULN
  • Any patient who has had a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon
  • Patients must have confirmed availability of archival or freshly biopsied tumor tissue meeting protocol-defined specifications (10 unstained slides) prior to study enrollment
  • Females of child-bearing potential (FOCBP) and males must agree to use adequate contraception (e.g. hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 28 days following completion of therapy; should a female patient, or a male patient's partner, become pregnant or suspect she is pregnant while participating in this study, the patient should inform her or his treating physician immediately

    • NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

      • Has not undergone a hysterectomy or bilateral oophorectomy
      • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)
  • FOCBP must have a negative pregnancy test (either urine or serum) within 14 days prior to registration

Exclusion Criteria:

  • Patients must not have any significant infections or medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate NU-0129
  • Patients must not have a history of any other cancer unless they are in complete remission and off of all therapy for that disease for a minimum of 3 years

    • Note: Non-melanoma skin cancer or carcinoma in-situ of the cervix are exceptions and may be permitted after discussion with study quality assurance manager (QAM)
  • Patients must not have had radiation therapy within 12 weeks prior to registration
  • Patients must not have had prior cancer therapy (including biologic, cytotoxic, and experimental therapies, nitrosoureas, and Gliadel wafers or other surgically implantable antitumor treatment) within 21 days of registration; if questions arise, please ask the principal investigator (PI)

    • NOTE: Patients must not have Novocure within 24 hours
  • Hormonal tumor therapies should not be administered within 14 days of registration; exceptions may be discussed with the PI
  • Patients must not have symptomatic hypertension
  • Patients with known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C are not eligible; Note: Patients do not need to have HIV, hepatitis B, or hepatitis C testing at screening
  • Female patients who are pregnant or breast feeding are not eligible
  • Patients are not eligible if they are unwilling or unable to comply with the protocol
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03020017
Other Study ID Numbers  ICMJE NU 16C01
STU00203790 ( CTRP (Clinical Trial Reporting Program) )
NU 16C01 ( Other Identifier: Northwestern University )
P30CA060553 ( U.S. NIH Grant/Contract )
NCI-2016-02007 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Priya Kumthekar, Northwestern University
Study Sponsor  ICMJE Northwestern University
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Priya Kumthekar, MD Northwestern University
PRS Account Northwestern University
Verification Date August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP